Biktarvy: Difference between revisions

[[Bictegravir]]/[[emtricitabine]]/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.<ref name="a4">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=664cb8f0-1f65-441b-b0d9-ba3d798be309 "Biktarvy- bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate tablet".] DailyMed. 8 August 2019. Retrieved 7 March 2020.</ref> It was approved for use in the United States in February 2018,<ref name="a5">[https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210251Orig1s000TOC.cfm "Drug Approval Package: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) Tablets".] U.S. Food and Drug Administration (FDA). 19 March 2018. Retrieved 7 March 2020.</ref><ref name="a6">[https://www.businesswire.com/news/home/20180207006071/en/U.S.-Food-Drug-Administration-Approves-Gilead%E2%80%99s-Biktarvy%C2%AE "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection"] (Press release). Gilead. 7 February 2018.</ref> and for use in the European Union in June 2018.<ref name="a7">[https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy "Biktarvy EPAR".] European Medicines Agency (EMA). 21 January 2020. Retrieved 7 March 2020.</ref>